Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2014 Jul 31;9(7):e101947. doi: 10.1371/journal.pone.0101947. eCollection 2014.

Optimal attenuation of experimental autoimmune encephalomyelitis by intravenous immunoglobulin requires an intact interleukin-11 receptor.

Author information

1
Research & Development, Canadian Blood Services, 67 College Toronto, Toronto, Ontario, Canada; Departments of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada.
2
Department of Immunology, University of Toronto, and Centre for Innovation, Canadian Blood Services, Toronto, Ontario, Canada.
3
Research & Development, Canadian Blood Services, 67 College Toronto, Toronto, Ontario, Canada.
4
Research & Development, Canadian Blood Services, 67 College Toronto, Toronto, Ontario, Canada; Departments of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada; Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada.
5
Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Immunology, University of Toronto, and Centre for Innovation, Canadian Blood Services, Toronto, Ontario, Canada; Women's College Research Institute, Toronto, Ontario, Canada.

Erratum in

  • PLoS One. 2014;9(11):e113001.

Abstract

BACKGROUND:

Intravenous immunoglobulin (IVIg) has been used to treat a variety of autoimmune disorders including multiple sclerosis (MS); however its mechanism of action remains elusive. Recent work has shown that interleukin-11 (IL-11) mRNAs are upregulated by IVIg in MS patient T cells. Both IVIg and IL-11 have been shown to ameliorate experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The objective of this study was to determine whether the protective effects of IVIg in EAE occur through an IL-11 and IL-11 receptor (IL-11R)-dependent mechanism.

METHODS:

We measured IL-11 in the circulation of mice and IL-11 mRNA expression in various organs after IVIg treatment. We then followed with EAE studies to test the efficacy of IVIg in wild-type (WT) mice and in mice deficient for the IL-11 receptor (IL-11Rα-/-). Furthermore, we evaluated myelin-specific Th1 and Th17 responses and assessed spinal cord inflammation and demyelination in WT and IL-11Rα-/- mice, with and without IVIg treatment. We also examined the direct effects of mouse recombinant IL-11 on the production of IL-17 by lymph node mononuclear cells.

RESULTS:

IVIg treatment induced a dramatic surge (>1000-fold increase) in the levels of IL-11 in the circulation and a prominent increase of IL-11 mRNA expression in the liver. Furthermore, we found that IL-11Rα-/- mice, unlike WT mice, although initially protected, were resistant to full protection by IVIg during EAE and developed disease with a similar incidence and severity as control-treated IL-11Rα-/- mice, despite initially showing protection. We observed that Th17 cytokine production by myelin-reactive T cells in the draining lymph nodes was unaffected by IVIg in IL-11Rα-/- mice, yet was downregulated in WT mice. Finally, IL-11 was shown to directly inhibit IL-17 production of lymph node cells in culture.

CONCLUSION:

These results implicate IL-11 as an important immune effector of IVIg in the prevention of Th17-mediated autoimmune inflammation during EAE.

PMID:
25078447
PMCID:
PMC4117465
DOI:
10.1371/journal.pone.0101947
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center